Imugene Limited's Announcement at 2024 Cholangiocarcinoma Foundation Annual Conference

Imugene Limited (ASX: $IMU) has announced that its CF33-hNIS (VAXINIA) technology has been chosen for a short oral presentation and a poster session at the 2024 Cholangiocarcinoma Foundation Annual Conference, scheduled for 17-19 April 2024 in Salt Lake City, Utah. The abstract, titled 'CF33-hNIS, a novel oncolytic virus for the treatment of cholangiocarcinoma and biliary tract malignancies,' suggests that CF33-hNIS monotherapy may be an effective and safe treatment option for GI malignancies, including cholangiocarcinoma, addressing an unmet medical need.

Executive Commentary on VAXINIA Presentation

The VAXINIA technology being selected for oral and poster presentations at the 2024 Cholangiocarcinoma Foundation Annual Conference is a significant achievement for Imugene. This opportunity allows us to showcase the potential of CF33-hNIS in addressing the unmet medical need for effective and safe treatment options for cholangiocarcinoma and biliary tract malignancies. We are committed to advancing the understanding and treatment of cholangiocarcinoma, and this recognition at the conference is a testament to our dedication to developing innovative cancer immunotherapies.

Summary of Imugene's Announcement

Imugene Limited (ASX: $IMU) has announced the selection of its CF33-hNIS (VAXINIA) technology for oral and poster presentations at the 2024 Cholangiocarcinoma Foundation Annual Conference. The abstract suggests that CF33-hNIS monotherapy may offer an effective and safe treatment option for GI malignancies, including cholangiocarcinoma, a rare disease with an unmet medical need. The conference, dedicated to advancing the understanding and treatment of cholangiocarcinoma, provides a unique platform for sharing the latest advancements in research, clinical trials, and patient care. Imugene's vision is to transform and improve the treatment of cancer, and the selection of VAXINIA for presentations at this conference aligns with the company's goal to be at the forefront of developing innovative cancer immunotherapies.